Intelligence Profile
Research Papers
Research on HB-adMSCs (Human Adipose-Derived Mesenchymal Stem Cells) covers a range of conditions, primarily focusing on neurological disorders, COVID-19, and autoimmune diseases.
A 2026 randomized, double-blind clinical trial published in "Parkinson's Disease" studied the effects of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells on Parkinson's patients. This trial provides significant insights into the potential therapeutic benefits for neurological conditions.
In a related area, a 2026 study in "Brain" explored the use of these stem cells for chronic traumatic brain injury, indicating potential avenues for recovery, though specifics on sample size and outcomes were not detailed.
For Parkinson's, another significant study was carried out, reported in "Cytotherapy" in 2025, examining the safety and efficacy of these stem cells in elderly patients. This study was part of an extended access program, reflecting ongoing research interest and application in a real-world setting.
Case reports also highlight individual successes using HB-adMSCs in severe neurological damage. Notably, a 2023 report in "Frontiers in Transplantation" described functional recovery in a quadriplegic patient following multiple infusions, though such anecdotal evidence requires further validation through controlled studies.
The safety of these interventions has been a concern, particularly in vulnerable populations such as hospitalized COVID-19 patients. A 2023 randomized controlled trial in "Frontiers in Medicine" investigated this, adding to the international effort to find safe treatments during the pandemic. Similarly, an expanded access program for post-COVID-19 syndrome was highlighted in "Stem Cell Research & Therapy" in 2023, showcasing ongoing trials and real-world applicability.
Autoimmune conditions' treatment potential was highlighted in a 2022 case report from the "Journal of Translational Autoimmunity," investigating dose effects in systemic lupus erythematosus patients.
Clinical trials on various conditions, like erectile dysfunction post-prostate surgery and COVID-19, further illustrate the broad potential applications of HB-adMSCs. However, some trials have been terminated or are no longer available, indicating challenges in bringing these therapies to wider clinical use.
Overall, while research is promising, the evidence primarily consists of small studies and case reports, emphasizing the need for larger, more rigorous studies to confirm these findings and assess long-term safety and efficacy.
Disclaimer: This summary is for informational purposes only and should not be considered medical advice. Consult healthcare professionals for personalized recommendations.